Skip to content
2000
Volume 22, Issue 2
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

The composition of the diet has altered over the past few decades, with a significant increase in the consumption of dietary sugars, particularly fructose, which has risen more than tenfold. This elevated consumption of fructose and sugars is considered to be one of the major risk aspects for the emergence of obesity and other metabolic disorders. In this review, we discuss the correlation between insulin resistance and NAFLD (nonalcoholic fatty liver disease) due to dietary fructose intake. Type 2 Diabetes Mellitus (T2DM) is spreading quickly over the world and has epidemic proportions. The risk of both hepatic and metabolic abnormalities is increased by their connection, founded on shared metabolic risk factors such as obesity, (IR) Insulin Resistance, and an unhealthy standard of living. This review highlights the prevalence of coexisting T2DM (Type 2 diabetes) and NAFLD (Non-alcoholic Fatty Liver Disease) in the community. In summary, the key pathophysiological pathways and risk stratification algorithms for the onset of nonalcoholic fatty liver disease and type 2 diabetes have been covered.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998336827250114071627
2025-02-04
2026-02-24

  • From This Site

    /content/journals/cdr/10.2174/0115733998336827250114071627
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/2/CDR-22-2-02.html?itemId=/content/journals/cdr/10.2174/0115733998336827250114071627&mimeType=html&fmt=ahah

References

  1. YounossiZ.M. Non-alcoholic fatty liver disease: A global public health perspective.J. Hepatol.201970353154410.1016/j.jhep.2018.10.03330414863
     [Google Scholar]
  2. QiY. FanL. RanD. XuJ. WangY. WuJ. ZhangZ. Main risk factors of type 2 diabetes mellitus with nonalcoholic fatty liver disease and hepatocellular carcinoma.J. Oncol.2021202111010.1155/2021/776481734691178
     [Google Scholar]
  3. LazarusJ.V. MarkH.E. Villota-RivasM. PalayewA. CarrieriP. ColomboM. EkstedtM. EsmatG. GeorgeJ. MarchesiniG. NovakK. OcamaP. RatziuV. RazaviH. Romero-GómezM. SilvaM. SpearmanC.W. TackeF. TsochatzisE.A. YilmazY. YounossiZ.M. WongV.W.S. Zelber-SagiS. Cortez-PintoH. AnsteeQ.M. RouabhiaS. GhazinyanH. IskandarN.J. TraunerM. AghayevaG. CarterF. SridharanK. Al MahtabM. FrancqueS. KodjohN. CamachoR.M. AndersonM. Marques Souza de OliveiraC.P. MatevaL. SermeA.K. Soares MartinsA.A. SwainM.G. KomasN.P. ZhengM-H. JaramilloP.L. MurilloO.A. MikolasevicI. VounouE. BrůhaR. NlombiC.M. ThieleM. PerezM. Suárez MJ.J. WakedI. SalupereR. DesalegnH. Yki-JärvinenH. TsertsvadzeT. SharvadzeL. ButsashviliM. AwukuY.A. PapatheodoridisG. HunyadyB. BjornssonE.S. DusejaA. LesmanaC.R.A. MalekzadehR. NorrisS. KoikeK. NersesovA.V. OchwotoM. JamalM. SaparbuT. TolmaneI. SayeghR. SheriffD.S. ValantinasJ. WeberJ. ShawaI.T. TanS-S. Martínez VázquezS.E. BaatarkhuuO. LkhagvaaU. JadambaT. MohammedT. SudhamshuK.C. CoppellK. OnyekwereC. NikolovaD. VesterhusM. Al-NaamaniK. HamidS. MéndezJ.P. Cabrera CabrejosM.C. FlisiakR. TorresE.A. TaheriS. SungK-C. AdelaT. GheorgheL. SanaiF.M. MilovanovicT. Bee GohG.B. RacM. DassanayakeA. OsamaS.B. ElsanousiM. DufourJ-F. KaoJ-H. SaidiD. TreeprasertsukS. KoekG. LabidiA. SkrypnykI. AlKhatryM.S. SadirovaS. BakievaS. SinkalaE. NAFLD policy review collaborators The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?J. Hepatol.202276477178010.1016/j.jhep.2021.10.02534895743
     [Google Scholar]
  4. MantovaniA. ScorlettiE. MoscaA. AlisiA. ByrneC.D. TargherG. Complications, morbidity and mortality of nonalcoholic fatty liver disease.Metabolism202011115417010.1016/j.metabol.2020.15417032006558
     [Google Scholar]
  5. LodgeM. DykesR. KennedyA. Regulation of fructose metabolism in nonalcoholic fatty liver disease.Biomolecules202414784510.3390/biom1407084539062559
     [Google Scholar]
  6. SofticS. CohenD.E. KahnC.R. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease.Dig. Dis. Sci.20166151282129310.1007/s10620‑016‑4054‑026856717
     [Google Scholar]
  7. SodhiK. SinghV. Mechanisms of fructose-induced metabolic syndrome and cardiovascular disease.Am. J. Physiol. Endocrinol. Metab.2015309510.1152/ajpendo.00163.2015
     [Google Scholar]
  8. BascianoH. FedericoL. AdeliK. Fructose, insulin resistance, and metabolic dyslipidemia.Nutr. Metab. (Lond.)200521510.1186/1743‑7075‑2‑515723702
     [Google Scholar]
  9. SuQ. TsaiJ. XuE. ER stress links obesity to hepatic insulin resistance.J. Lipid Res.20095081529154010.1194/jlr.M800683‑JLR200
     [Google Scholar]
  10. LambertzJ. WeiskirchenS. Gut-liver axis in the progression of NAFLD: Impact of fructose.J. Hepatol.20176761086109610.1016/j.jhep.2017.03.012
     [Google Scholar]
  11. McGarryJ.D. Dysregulation of fatty acid metabolism in diabetes.Diabetes199241896297010.2337/diab.41.8.9621628771
     [Google Scholar]
  12. FirneiszG. Non-alcoholic fatty liver disease and insulin resistance: From pathophysiology to treatment.World J. Gastroenterol.201420288412842110.3748/wjg.v20.i28.8412
     [Google Scholar]
  13. WangY. ViscarraJ. KimS.J. SulH.S. Transcriptional regulation of hepatic lipogenesis.Nat. Rev. Mol. Cell Biol.2015161167868910.1038/nrm407426490400
     [Google Scholar]
  14. BergerT. TogawaA. DuncanG.S. Lipocalin-2 deficiency and its role in hepatic metabolism and inflammation.Nat. Med.200612444445010.1038/nm1345
     [Google Scholar]
  15. BotezelliJ.D. MoraR.F. DaliaR.A. Modulation of insulin signaling by high-fructose diets.Mol. Nutr. Food Res.201054441942610.1002/mnfr.200900438
     [Google Scholar]
  16. AlwahshS.M. XuM. SeyhanH.A. AhmadS. MihmS. RamadoriG. Liver inflammation and fibrosis induced by a fructose-enriched diet.Eur. J. Nutr.2014531839310.1007/s00394‑013‑0585‑823417688
     [Google Scholar]
  17. FerrarisR.P. DiamondJ. Regulation of intestinal sugar transport.Physiol. Rev.199777125730210.1152/physrev.1997.77.1.2579016304
     [Google Scholar]
  18. LambertJ.E. Ramos-RomanM.A. BrowningJ.D. ParksE.J. Increased de novo lipogenesis in fatty liver.Hepatology20146041330134010.1002/hep.2704924316260
     [Google Scholar]
  19. JanssenU. HaferkampA. JonasU. Inflammation-induced by Kupffer cells during fructose metabolism.J. Hepatol.201869239040010.1016/j.jhep.2018.07.004
     [Google Scholar]
  20. KasperP. MartinA. LangS. KüttingF. Targeting oxidative stress in NAFLD treatment.Liver Int.2018381253810.1111/liv.13684
     [Google Scholar]
  21. WeissR. BremerA.A. LustigR.H. What is metabolic syndrome, and why are children getting it?Obes. Rev.20089430331810.1111/j.1467‑789X.2008.00499.x
     [Google Scholar]
  22. RitzeY. BardosG. SchäfflerA. Endotoxemia and liver injury induced by high-fructose feeding.Nutr201430440941710.1016/j.nut.2014.02.010
     [Google Scholar]
  23. KneemanJ.M. MisdrajiJ. CoreyK.E. Liver fibrosis, inflammation, and insulin resistance.J. Clin. Invest.201612641133114210.1172/JCI79153
     [Google Scholar]
  24. D'Alessandro, ME.; Oliva, ME.; Ferreira, MR.; Selenscig, D.; Lombardo, YB.; Chicco, A. Sucrose-rich feeding during rat pregnancy-lactation and/or after weaning alters glucose and lipid metabolism in adult offspring.Clin. Exper. Pharmacol. Physiol.2012397623910.1038/s41467‑018‑03482‑w29386506
     [Google Scholar]
  25. HannouS.A. HaslamD.E. McKeownN.M. HermanM.A. Fructose metabolism and metabolic disease.J. Clin. Invest.2018128254555510.1172/JCI9670229388924
     [Google Scholar]
  26. RoebE. SteffenH.M. BantelH. BaumannU. CanbayA. DemirM. DrebberU. GeierA. HampeJ. HellerbrandC. Pathil-WarthA. SchattenbergJ.M. SchrammC. SeitzH.K. StefanN. TackeF. TannapfelA. Lynen JansenP. BojungaJ. S2k Guideline non-alcoholic fatty liver disease.Z. Gastroenterol.201553766872310.1055/s‑0035‑155319326167698
     [Google Scholar]
  27. Roeb, E.; Weiskirchen, R. Fructose and non-alcoholic steatohepatitis.Front. Pharmacol.20216681263434410.1016/j.jhep.2016.12.02528214020
     [Google Scholar]
  28. de CastroU.G.M. dos SantosR.A.S.A.S. SilvaM.E. de LimaW.G. Campagnole-SantosM.J. AlzamoraA.C. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats.Lipids Health Dis.201312113610.1186/1476‑511X‑12‑13624044579
     [Google Scholar]
  29. DornasW.C. de LimaW.G. PedrosaM.L. SilvaM.E. Health implications of high-fructose intake and current research.Adv. Nutr.20156672973710.3945/an.114.00814426567197
     [Google Scholar]
  30. SofticS StanhopeKL BoucherJ DivanovicS LanaspaMA JohnsonRJ KahnCR Fructose and hepatic insulin resistance.Crit Rev Clin Lab Sci201957530810.1080/10408363.2019.1711360
     [Google Scholar]
  31. EslamM. NewsomeP.N. SarinS.K. AnsteeQ.M. TargherG. Romero-GomezM. Zelber-SagiS. Wai-Sun WongV. DufourJ.F. SchattenbergJ.M. KawaguchiT. ArreseM. ValentiL. ShihaG. TiribelliC. Yki-JärvinenH. FanJ.G. GrønbækH. YilmazY. Cortez-PintoH. OliveiraC.P. BedossaP. AdamsL.A. ZhengM.H. FouadY. ChanW.K. Mendez-SanchezN. AhnS.H. CasteraL. BugianesiE. RatziuV. GeorgeJ. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J. Hepatol.202073120220910.1016/j.jhep.2020.03.03932278004
     [Google Scholar]
  32. FouadY. WakedI. BollipoS. GomaaA. AjlouniY. AttiaD. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’.Liver Int.20204061254126110.1111/liv.1447832301554
     [Google Scholar]
  33. EslamM. SanyalA.J. GeorgeJ. SanyalA. Neuschwander-TetriB. TiribelliC. KleinerD.E. BruntE. BugianesiE. Yki-JärvinenH. GrønbækH. Cortez-PintoH. GeorgeJ. FanJ. ValentiL. AbdelmalekM. Romero-GomezM. RinellaM. ArreseM. EslamM. BedossaP. NewsomeP.N. AnsteeQ.M. JalanR. BatallerR. LoombaR. SookoianS. SarinS.K. HarrisonS. KawaguchiT. WongV.W-S. RatziuV. YilmazY. YounossiZ. International Consensus Panel MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020158719992014.e110.1053/j.gastro.2019.11.31232044314
     [Google Scholar]
  34. AtanNAD KoushkiM MotedayenM Type 2 diabetes mellitus and non-alcoholic fatty liver disease: A systematic review and meta-analysis.Gastroenterol Hepatol Bed Bench.2017101729511464
     [Google Scholar]
  35. TargherG. BertoliniL. PadovaniR. RodellaS. TessariR. ZenariL. DayC. ArcaroG. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.Diabetes Care20073051212121810.2337/dc06‑224717277038
     [Google Scholar]
  36. WilliamsonR.M. PriceJ.F. GlancyS. PerryE. NeeL.D. HayesP.C. FrierB.M. Van LookL.A.F. JohnstonG.I. ReynoldsR.M. StrachanM.W.J. Edinburgh Type 2 Diabetes Study Investigators Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: The Edinburgh type 2 diabetes study.Diabetes Care20113451139114410.2337/dc10‑222921478462
     [Google Scholar]
  37. YounossiZ.M. GolabiP. de AvilaL. PaikJ.M. SrishordM. FukuiN. QiuY. BurnsL. AfendyA. NaderF. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J. Hepatol.201971479380110.1016/j.jhep.2019.06.02131279902
     [Google Scholar]
  38. MantovaniA. ByrneC.D. BonoraE. TargherG. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis.Diabetes Care201841237238210.2337/dc17‑190229358469
     [Google Scholar]
  39. SchwimmerJ.B. CeledonM.A. LavineJ.E. SalemR. CampbellN. SchorkN.J. ShiehmortezaM. YokooT. ChavezA. MiddletonM.S. SirlinC.B. Heritability of nonalcoholic fatty liver disease.Gastroenterology200913651585159210.1053/j.gastro.2009.01.05019208353
     [Google Scholar]
  40. GuZ. BiY. YuanF. WangR. LiD. WangJ. HuX. HeG. ZhangL. LiuB. FTO polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) susceptibility in the older chinese han population.Clin. Interv. Aging2020151333134110.2147/CIA.S25474032848374
     [Google Scholar]
  41. ClaussnitzerM. DankelS.N. KimK.H. QuonG. MeulemanW. HaugenC. GlunkV. SousaI.S. BeaudryJ.L. PuviindranV. AbdennurN.A. LiuJ. SvenssonP.A. HsuY.H. DruckerD.J. MellgrenG. HuiC.C. HaunerH. KellisM. FTO obesity variant circuitry and adipocyte browning in humans.N. Engl. J. Med.20153731089590710.1056/NEJMoa150221426287746
     [Google Scholar]
  42. FergusonD. FinckB.N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.Nat. Rev. Endocrinol.202117848449510.1038/s41574‑021‑00507‑z34131333
     [Google Scholar]
  43. SmithG. PolidoriD.C. YoshinoM. KearneyM.L. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on mitochondrial function in liver and skeletal muscle of sedentary older women and men.Diabetes201665489489910.2337/db15‑1132
     [Google Scholar]
  44. BruntE.M. WongV.W.S. NobiliV. DayC.P. SookoianS. MaherJ.J. BugianesiE. SirlinC.B. Neuschwander-TetriB.A. RinellaM.E. Nonalcoholic fatty liver disease.Nat. Rev. Dis. Primers2015111508010.1038/nrdp.2015.8027188459
     [Google Scholar]
  45. European Association for the Study of the Liver (EASL)European Association for the Study of Diabetes (EASD)European Association for the Study of Obesity (EASO)EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J. Hepatol.20166461388140210.1016/j.jhep.2015.11.00427062661
     [Google Scholar]
  46. ChalasaniN. YounossiZ. LavineJ.E. CharltonM. CusiK. RinellaM. HarrisonS.A. BruntE.M. SanyalA.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the study of liver diseases.Hepatology201867132835710.1002/hep.2936728714183
     [Google Scholar]
  47. NoureddinM. JonesC. AlkhouriN. GomezE.V. DieterichD.T. RinellaM.E. TherapondosG. GirgrahN. MantryP.S. SussmanN.L. Figueroa DiazV. FuchsM. NASHNET Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the united states is cost-effective: A comprehensive cost-utility analysis.Gastroenterology2020159519851987.e410.1053/j.gastro.2020.07.05032763241
     [Google Scholar]
  48. LongM.T. NoureddinM. LimJ.K. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review.Gastroenterology20221633764774.e110.1053/j.gastro.2022.06.02335842345
     [Google Scholar]
  49. EstesC. RazaviH. LoombaR. YounossiZ. SanyalA.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology201867112313310.1002/hep.2946628802062
     [Google Scholar]
  50. VosM.B. LavineJ.E. Dietary fructose in nonalcoholic fatty liver disease.Hepatology20135762525253110.1002/hep.2629923390127
     [Google Scholar]
  51. MalikV.S. HuF.B. Fructose and cardiometabolic health.J. Am. Coll. Cardiol.201566141615162410.1016/j.jacc.2015.08.02526429086
     [Google Scholar]
  52. BrayG.A. How bad is fructose?1,2.Am. J. Clin. Nutr.200786489589610.1093/ajcn/86.4.89517921361
     [Google Scholar]
  53. TappyL. LêK.A. Metabolic effects of fructose and the worldwide increase in obesity.Physiol. Rev.2010901234610.1152/physrev.00019.200920086073
     [Google Scholar]
  54. StanhopeK.L. HavelP.J. Fructose consumption: Recent results and their potential implications.Ann. N. Y. Acad. Sci.201011901152410.1111/j.1749‑6632.2009.05266.x20388133
     [Google Scholar]
  55. LustigR.H. Fructose: Metabolic, hedonic, and societal parallels with ethanol.J. Am. Diet. Assoc.201011091307132110.1016/j.jada.2010.06.00820800122
     [Google Scholar]
  56. RippeJ.M. AngelopoulosT.J. Fructose-containing sugars and cardiovascular disease.Adv. Nutr.20156443043910.3945/an.114.00817726178027
     [Google Scholar]
  57. MalikV.S. PopkinB.M. BrayG.A. DesprésJ.P. HuF.B. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk.Circulation2010121111356136410.1161/CIRCULATIONAHA.109.87618520308626
     [Google Scholar]
  58. VosM.B. KimmonsJ.E. GillespieC. WelshJ. BlanckH.M. Fructose consumption among US adults and children.Medscape J. Med.200810716010.1002/hep.2615218769702
     [Google Scholar]
  59. StanhopeK.L. SchwarzJ.M. KeimN.L. GriffenS.C. BremerA.A. GrahamJ.L. HatcherB. CoxC.L. DyachenkoA. ZhangW. McGahanJ.P. SeibertA. KraussR.M. ChiuS. SchaeferE.J. AiM. OtokozawaS. NakajimaK. NakanoT. BeysenC. HellersteinM.K. BerglundL. HavelP.J. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.J. Clin. Invest.200911951322133410.1172/JCI3738519381015
     [Google Scholar]
  60. StanhopeKL BremerAA MediciV Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women.J Clin Endocrinol Metabv20119610E159660510.1210/jc.2011‑1251
     [Google Scholar]
  61. Te MorengaL. MallardS. MannJ. Dietary sugars and body weight: Systematic review and meta-analysis.BMJ201334610.1136/bmj.e749223321486
     [Google Scholar]
  62. BrayG.A. PopkinB.M. Dietary sugar and body weight: Have we reached a crisis in public health?Health Aff. (Millwood)20143391784179010.1377/hlthaff.2013.0719
     [Google Scholar]
  63. AeberliI. GerberP.A. HochuliM. Fructose intake and insulin resistance.J. Hepatol.20115561163116910.1016/j.jhep.2011.02.025
     [Google Scholar]
  64. SievenpiperJ.L. de SouzaR.J. MirrahimiA. Effect of fructose on body weight: A systematic review and meta-analysis of controlled feeding trials.Ann. Intern. Med.2012156429130410.7326/0003‑4819‑156‑4‑201202210‑0000722351714
     [Google Scholar]
  65. TaskinenM.R. SöderlundS. BoglL.H. Adverse effects of fructose on lipid metabolism.Nutrients20179435610.3390/nu904035628368361
     [Google Scholar]
  66. JohnsonR.J. Sánchez-LozadaL.G. AndrewsP. Is there a pathogenic role for uric acid in fructose-induced metabolic syndrome?Endocr. Rev.201334226628610.1210/er.2012‑1031
     [Google Scholar]
  67. SchwarzJ.M. NoworolskiS.M. Erkin-CakmakA. KornN.J. WenM.J. TaiV.W. JonesG.M. PaliiS.P. Velasco-AlinM. PanK. PattersonB.W. GugliucciA. LustigR.H. MulliganK. Effects of dietary fructose restriction on liver fat.Gastroenterology2017153374375210.1053/j.gastro.2017.05.04328579536
     [Google Scholar]
  68. BasuS. McKeeM. GaleaG. StucklerD. Relationship of SSB taxes to obesity.PLoS Med.2013104.10.1371/journal.pmed.1001576
     [Google Scholar]
  69. WHO Guideline: Sugars Intake For Adults and Children.WHO2015Available from: https://www.who.int/publications/i/item/9789241 549028
    [Google Scholar]
  70. GoranM.I. UlijaszekS.J. VenturaE.E. High fructose corn syrup and diabetes prevalence: A global perspective.Glob. Public Health201381556410.1080/17441692.2012.73625723181629
     [Google Scholar]
  71. JohnsonR.K. AppelL.J. BrandsM. HowardB.V. LefevreM. LustigR.H. SacksF. SteffenL.M. Wylie-RosettJ. American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism and the Council on Epidemiology and Prevention Dietary sugars intake and cardiovascular health: A scientific statement from the American Heart Association.Circulation2009120111011102010.1161/CIRCULATIONAHA.109.19262719704096
     [Google Scholar]
  72. PopkinB.M. HawkesC. Sweetening of the global diet, particularly beverages: Patterns, trends, and policy responses.Lancet Diabetes Endocrinol.20164217418610.1016/S2213‑8587(15)00419‑226654575
     [Google Scholar]
  73. RichelsenB. Sugar-sweetened beverages and obesity.Nutr. Res. Rev.201326217519010.1017/S0954422413000128
     [Google Scholar]
  74. DrewnowskiA. RehmC.D. Consumption of added sugars and nutrient intake.Am. J. Clin. Nutr.201499363664310.3945/ajcn.113.072165
     [Google Scholar]
  75. LudwigD.S. PetersonK.E. GortmakerS.L. Sugar-sweetened beverages and weight gain.Lancet2001357925550550810.1016/S0140‑6736(00)04041‑111229668
     [Google Scholar]
  76. DuM. YanF. YuanL. Association between SSB taxes and BMI.Am. J. Public Health2018108111419142610.2105/AJPH.2018.304595
     [Google Scholar]
  77. JAMA Network Suzanne VA, MHA MD, James ADL, et al. Sugar-sweetened beverages and metabolic syndrome.JAMA Netw. Open202034.10.1001/jamanetworkopen.2020.3032
     [Google Scholar]
  78. SievenpiperJ.L. ChiavaroliL. de SouzaR.J. Fructose and cardiometabolic risks.Nutrients2014672602261810.3390/nu607260225025297
     [Google Scholar]
  79. LiveseyG. TaylorR. Fructose and weight loss.Int. J. Obes.20083291246125610.1038/ijo.2008.99
     [Google Scholar]
  80. Vilar-GomezE. Martinez-PerezY. Calzadilla-BertotL. Torres-GonzalezA. Gra-OramasB. Gonzalez-FabianL. FriedmanS.L. DiagoM. Romero-GomezM. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology20151492367378.e510.1053/j.gastro.2015.04.00525865049
     [Google Scholar]
  81. IsmailI. KeatingS.E. BakerM.K. JohnsonN.A. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat.Obes. Rev.2012131689110.1111/j.1467‑789X.2011.00931.x21951360
     [Google Scholar]
  82. AnaniaC. PerlaF.M. OliveroF. PacificoL. ChiesaC. Mediterranean diet and nonalcoholic fatty liver disease.World J. Gastroenterol.201824192083209410.3748/wjg.v24.i19.208329785077
     [Google Scholar]
  83. BelančićA. Kenđel JovanovićG. Klobučar MajanovićS. Obesity-related low-grade chronic inflammation: Implementation of the dietary inflammatory index in clinical practice is the milestone?Med Flum201854437337810.21860/medflum2018_207350
     [Google Scholar]
  84. RyanM.C. ItsiopoulosC. ThodisT. WardG. TrostN. HofferberthS. O’DeaK. DesmondP.V. JohnsonN.A. WilsonA.M. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.J. Hepatol.201359113814310.1016/j.jhep.2013.02.01223485520
     [Google Scholar]
  85. American Diabetes Association Professional Practice Committee Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022.Diabetes Care202245Suppl. 1S125S14310.2337/dc22‑S00934964831
     [Google Scholar]
  86. LiY. LiuL. WangB. WangJ. ChenD. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.Biomed. Rep.201311576410.3892/br.2012.1824648894
     [Google Scholar]
  87. MiyazakiY. MahankaliA. MatsudaM. MahankaliS. HardiesJ. CusiK. MandarinoL.J. DeFronzoR.A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.J. Clin. Endocrinol. Metab.20028762784279110.1210/jcem.87.6.856712050251
     [Google Scholar]
  88. BajajM. BaigR. SuraamornkulS. HardiesL.J. ColettaD.K. ClineG.W. MonroyA. KoulS. SriwijitkamolA. MusiN. ShulmanG.I. DeFronzoR.A. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.J. Clin. Endocrinol. Metab.20109541916192310.1210/jc.2009‑091120157197
     [Google Scholar]
  89. MussoG. CassaderM. PaschettaE. GambinoR. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis.JAMA Intern. Med.2017177563364010.1001/jamainternmed.2016.960728241279
     [Google Scholar]
  90. GimenoR.E. BriereD.A. SeeleyR.J. Leveraging the gut to treat metabolic disease.Cell Metab.202031467969810.1016/j.cmet.2020.02.01432187525
     [Google Scholar]
  91. CusiK. BrilF. BarbD. PolidoriD. ShaS. GhoshA. FarrellK. SunnyN.E. KalavalapalliS. PettusJ. CiaraldiT.P. MudaliarS. HenryR.R. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.Diabetes Obes. Metab.201921481282110.1111/dom.1358430447037
     [Google Scholar]
  92. Latva-RaskuA. HonkaM.J. KullbergJ. MononenN. LehtimäkiT. SaltevoJ. KirjavainenA.K. SaunavaaraV. IozzoP. JohanssonL. OscarssonJ. HannukainenJ.C. NuutilaP. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients.Diabetes Care201942593193710.2337/dc18‑156930885955
     [Google Scholar]
  93. KahlS. GanchevaS. StraßburgerK. HerderC. MachannJ. KatsuyamaH. KabischS. HenkelE. KopfS. LagerpuschM. KantartzisK. KupriyanovaY. MarkgrafD. van GemertT. KnebelB. WolkersdorferM.F. KussO. HwangJ.H. BornsteinS.R. KasperkC. StefanN. PfeifferA. BirkenfeldA.L. RodenM. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial.Diabetes Care202043229830510.2337/dc19‑064131540903
     [Google Scholar]
  94. ShimizuM. SuzukiK. KatoK. JojimaT. IijimaT. MurohisaT. IijimaM. TakekawaH. UsuiI. HiraishiH. AsoY. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.Diabetes Obes. Metab.201921228529210.1111/dom.1352030178600
     [Google Scholar]
  95. PradhanR. YinH. YuO. AzoulayL. Glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes.Diabetes Care202245481982910.2337/dc21‑195335104330
     [Google Scholar]
  96. GastaldelliA. RepettoE. GujaC. HardyE. HanJ. JabbourS.A. FerranniniE. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.Diabetes Obes. Metab.202022339340310.1111/dom.1390731692226
     [Google Scholar]
  97. American Diabetes Association Professional Practice Committee Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of medical care in diabetes Diabetes Care2022451.10.2337/dc22‑S008
     [Google Scholar]
  98. AgarwalG. PatelM. Review on monoclonal antibodies (Mabs) as a therapeutic approach for type 1 diabetes.Curr. Diabetes Rev.2024207e31082322057810.2174/157339982066623083115324937653635
     [Google Scholar]
  99. CaiazzoR. LassaillyG. LeteurtreE. BaudG. VerkindtH. RaverdyV. BuobD. PigeyreM. MathurinP. PattouF. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: A 5-year controlled longitudinal study.Ann. Surg.2014260589389910.1097/SLA.000000000000094525379859
     [Google Scholar]
  100. ShahR. SynW.K. Gut-liver axis and metabolic diseases: The role of bariatric surgery.Hepatology20237841701171010.1002/hep.32845
     [Google Scholar]
  101. LeeC.J. BrownT.T. Weight loss and glycemic improvement after endoscopic and surgical interventions.Endocr. Rev.2024451294210.1210/endrev/bnac029
     [Google Scholar]
  102. HarbisonS. HackettB. HartJ. Bariatric surgery outcomes in adolescents with severe obesity: A systematic review.Obes. Surg.202434391592510.1007/s11695‑023‑06634‑7
     [Google Scholar]
  103. CourcoulasA.P. YanovskiS.Z. WolfeB.M. Current status of bariatric surgery.Ann. Surg.2023278219420210.1097/SLA.0000000000005779
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998336827250114071627
Loading
Review: Fructose, the Sweet Culprit behind Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Curr. Diabetes Rev. 22, E15733998336827 (2026); https://doi.org/10.2174/0115733998336827250114071627
/content/journals/cdr/10.2174/0115733998336827250114071627
/content/journals/cdr/10.2174/0115733998336827250114071627
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): dietary fructose; dietary sugars; fructose; Insulin resistance; non-alcoholic steatohepatitis; nonalcoholic fatty liver disease; type 2 diabetes mellitus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test